Human Trials

GDNF trial yields promising results for treatment of Parkinson’s Disease

A clinical trial held in the UK in patients with Parkinson’s Disease showed that it could be possible to restore damaged neurons by boosting the levels of a naturally-occurring protein called Glial Cell Line Derived Neurotrophic Factor (GDNF).

Nuformix announces UK MHRA approval to start NXP001 human pharmacokinetics studies

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence human pharmacokinetics studies for the Company's lead asset NXP001.

Brilinta’s phase 3 THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.

Sosei Heptares doses first patient in trial targeting endocrine disorders

Sosei Group announced that the first healthy subject has been dosed with a small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program targeting endocrine disorders, including Cushing’s disease.

Innovent, Chipscreen Biosciences to assess combination therapy in colorectal cancer patients

Innovent has entered into a collaboration with Shenzhen Chipscreen Biosciences to evaluate a combination therapy made up of their respective drugs in colorectal cancer patients.

Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug

Bionomics has announced that further data analysis of its phase 2 post traumatic stress disorder (PTSD) trial demonstrated the potential for significant patient benefit when drug exposure is adequate.

Bavencio plus Inlyta improves median PFS in renal carcinoma study

Pfizer and Merck have announced that Bavencio (avelumab) plus Inlyta (axitinib) has improved median progression-free survival (PFS) in renal carcinoma study.

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).

Boehringer Ingelheim, IBM to integrate blockchain technology into clinical trials

Boehringer Ingelheim (Canada) and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials.